JOA - 2026-10-01 - Journal Article
Intraoperative Vancomycin Does Not Change Periprosthetic Joint Infection Risk in Patients Undergoing Total Joint Arthroplasty.
Jiang WM, Sanchez JG, Halperin SJ, Molloy IB, Grauer JN, Rubin LE
Topics
Key Takeaway
Intraoperative vancomycin added to cefazolin prophylaxis did not reduce 90-day PJI or SSI rates, nor improve 5-year revision-free survival in 60,620 matched THA and 87,138 matched TKA patients.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study used a national database to compare 90-day infectious complications and 5-year revision-free survival between primary THA and TKA patients who received intraoperative vancomycin plus cefazolin versus cefazolin alone, with 1:1 propensity matching on age, sex, BMI, comorbidities, and region. Vancomycin was used in 26.5% of THA and 28.7% of TKA cases. Across both procedures, intraoperative vancomycin was not associated with reduced odds of superficial SSI or PJI at 90 days, nor with improved 5-year revision-free survival under Bonferroni-corrected significance thresholds (P<0.003).
Key Limitation
Route of vancomycin administration (intrawound, intraosseous, or intravenous) cannot be differentiated in the database, precluding conclusions about whether any specific delivery method confers benefit.
Original Abstract
BACKGROUND
Cephalosporins are the primary prophylactic antibiotic in primary total hip and knee arthroplasty (THA and TKA). There is interest in augmenting this effect by adding intraoperative vancomycin via intrawound, intraosseous, or intravenous routes. However, low periprosthetic joint infection (PJI) rates have hindered statistical power and consensus within prior research. This study aimed to compare 90-day infectious and medical complications and 5-year revision-free survival among patients who did and did not have intraoperative vancomycin within a large, nationally representative population.
METHODS
Within a national database, adult patients undergoing primary THA or TKA for osteoarthritis from January 2010 to April 2023 who received same-day cefazolin prophylaxis were identified. Exclusion criteria included methicillin-resistant Staphylococcus aureus or PJI history, prior infection within 90 days, and any antibiotic prescription within 90 days before and three days following surgery. Patients who did and did not have the addition of intraoperative vancomycin were matched (1:1) on age, sex, Elixhauser Comorbidity Index, body mass index greater than 40, type II diabetes, insulin use, smoking status, and geographic region. Among 78,778 THA patients, 20,841 (26.5%) received intraoperative vancomycin, yielding 17,051 matched patients per group. Among 171,274 TKA patients, 49,145 (28.7%) received vancomycin, yielding 43,569 matched patients per group. The 90-day complications were assessed using univariable and multivariable logistic regressions. The 5-year revision-free survival was evaluated with Kaplan-Meier analysis and log-rank testings. Significance was defined as P < 0.003, per Bonferroni correction.
RESULTS
Across both procedures, intraoperative vancomycin was not associated with reduced 90-day odds of superficial surgical site infection or PJI, nor increased odds of any other adverse event. The 5-year revision-free survival was comparable between both the THA and TKA matched groups.
CONCLUSIONS
In this cohort, intraoperative vancomycin was not associated with lower odds of 90-day surgical site infection or PJI, nor improved 5-year revision-free survival.